| Systemic drug therapy and restenosis after drug-eluting stent implantation |
|
Kyoo-Rok Han |
|
한림대학교 의과대학 내과학교실 강동성심병원 심혈관센터 |
| 논평 : 약물요법으로 약물방출 스텐트 시술 후 재협착을 더 줄일 수 있나? |
|
한규록 |
|
|
|
|
|
|
| Abstract |
|
Until now restenosis is one of the most important issues after stent implantation. Use of systemic drug therapy to inhibit post-stent restenosis has been largely unsuccessful. Drug-eluting stents (DES) have been shown to significantly reduce restenosis after percutaneous coronary intervention. However we still experience lots of problems associated with restenosis even after DES implantation. Recently some clinical trials have suggested that cilostazol reduces intimal hyperplasia and lowers restenosis after bare metal stents (BMS) implantation. It is uncertain that cilostazol can also reduce restenosis after DES implantation. We need more large clinical trials to elucidate the efficacy of cilostazol on restenosis after DES implantation. (Korean J Med 74:366-367, 2008) |
| Key Words:
Drug-eluting stent; Restenosis; Systemic drug therapy; Cilostazol |
PDF Links
Full text via DOI
Download Citation
